Nama's AI scorecard currently rates Waystar Buy (6.2 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

What is WAY's P/E ratio?

Waystar trades at a trailing price-to-earnings ratio of 17.2.

When does WAY report earnings?

Waystar's next scheduled report is on Feb 17, 2027. Analysts expect EPS of $0.41.

What is the WAY price target?

The median analyst price target from 22 analysts is $34.00, with a range of $28.00 – $44.00.

Is WAY Shariah compliant?

Nama's AAOIFI-style screen reads Waystar as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.

Nama Insights

Waystar (WAY)

Healthcare · Health Information Services · NASDAQ

Waystar (WAY) is a Healthcare company in the Health Information Services industry. It has a market capitalization of $5.45B, a trailing price-to-earnings ratio of 17.2 and a free-cash-flow yield of 5.4%. Over the most recent reported fiscal year, revenue grew 16.5% and free cash flow per share grew 61.2%. Nama's AI scorecard rates it Buy, 6.2 out of 10. On 12-month momentum it ranks in the trailing band of its market.

AI scorecard

Buy · 6.2/10

Positive, at the low end of Buy. As of Nov 7, 2026.

Momentum

Trailing · -28.0% over 12 months ex. last

Bottom 20% of its market on the past year's move.

Shariah screen

Shariah Compliant

Passes our debt, cash and income screen; not a scholar's ruling.

Off its high

-41.1%

How far the last close sits under the highest price of the past five years.

Market cap	$5.45B
Trailing P/E	17.2
Price / book	1.4
Price / sales	4.5
FCF yield	5.4%
Dividend yield	—
Gross margin	69.1%
Operating margin	22.9%
Net margin	11.2%
Revenue growth (YoY)	+16.5%
Revenue growth (3-yr annual)	+16.0%
EPS growth (YoY)	—
FCF/share growth (YoY)	+61.2%
Beta	0.2
Exchange	NASDAQ
Sector	Healthcare
Industry	Health Information Services

WAY earnings

Next report: Feb 17, 2027 (Q4 2026, EPS estimate $0.41). Beat the EPS estimate in 3 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q3 2026	Nov 2, 2026	$0.44	$0.41	+7.3%	$325.62M
Q2 2026	Jul 29, 2026	$0.43	$0.40	+7.5%	$319.67M
Q1 2026	Apr 29, 2026	$0.42	$0.39	+7.7%	$313.87M
Q4 2025	Feb 17, 2026	$0.36	$0.40	-10.0%	$303.54M

WAY analyst price target

Median target $34.00 from 22 analysts, ranging $28.00 – $44.00.

Health Information Services peers

Ticker	Company	Market cap	P/E
VEEV	Veeva Systems	$49.18B	35.0
TEM	Tempus AI	$13.87B	—
BTSG	BrightSpring Health Services	$13.36B	39.3
HNGE	Hinge Health	$9.34B	51.7
HQY	HealthEquity	$8.57B	23.3
TXG	10x Genomics	$7.72B	296.4
DOCS	Doximity	$5.79B	23.7
HTFL	Heartflow	$4.56B	—

Explore live WAY data on Nama Insights →

WAY FAQ

Is WAY a buy?: Nama's AI scorecard currently rates Waystar Buy (6.2 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
What is WAY's P/E ratio?: Waystar trades at a trailing price-to-earnings ratio of 17.2.
When does WAY report earnings?: Waystar's next scheduled report is on Feb 17, 2027. Analysts expect EPS of $0.41.
What is the WAY price target?: The median analyst price target from 22 analysts is $34.00, with a range of $28.00 – $44.00.
Is WAY Shariah compliant?: Nama's AAOIFI-style screen reads Waystar as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.